ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC

[1]  U. Förstermann,et al.  Protein kinase C α promotes angiogenic activity of human endothelial cells via induction of vascular endothelial growth factor , 2008 .

[2]  A. Gartel,et al.  Differential sensitivity of human colon cancer cell lines to the nucleoside analogs ARC and DRB , 2008, International journal of cancer.

[3]  A. Gartel,et al.  Proapoptotic compound ARC targets Akt and N-myc in neuroblastoma cells , 2008, Oncogene.

[4]  U. Förstermann,et al.  Protein kinase C alpha promotes angiogenic activity of human endothelial cells via induction of vascular endothelial growth factor. , 2008, Cardiovascular research.

[5]  S. Kojima,et al.  Inhibition of tumor angiogenesis by targeting endothelial surface ATP synthase with sangivamycin. , 2007, Japanese journal of clinical oncology.

[6]  D. Chauhan,et al.  The therapeutic role of targeting protein kinase C in solid and hematologic malignancies , 2007, Expert opinion on investigational drugs.

[7]  A. Gartel,et al.  A novel anticancer agent ARC antagonizes HIV-1 and HCV , 2007, Oncogene.

[8]  M. Jung,et al.  The Nucleoside Analog Sangivamycin Induces Apoptotic Cell Death in Breast Carcinoma MCF7/Adriamycin-resistant Cells via Protein Kinase Cδ and JNK Activation* , 2007, Journal of Biological Chemistry.

[9]  T. Robak,et al.  Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. , 2006, Current medicinal chemistry.

[10]  B. Teicher.  Protein Kinase C as a Therapeutic Target , 2006, Clinical Cancer Research.

[11]  A. Gartel,et al.  A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity. , 2006, Cancer research.

[12]  D. Selwood,et al.  Anticancer Drug Development: Preclinical Screening, Clinical Trials and Approval , 2004, British Journal of Cancer.

[13]  C. Sergheraert,et al.  Synthetic hispidin, a PKC inhibitor, is more cytotoxic toward cancer cells than normal cells in vitro , 1997, Cell Biology and Toxicology.

[14]  W. Plunkett,et al.  Cellular and Clinical Pharmacology of Fludarabine , 2002, Clinical pharmacokinetics.

[15]  K. Umezawa,et al.  Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells. , 2001, International journal of oncology.

[16]  B. Cheson,et al.  Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[17]  K. Kinzler,et al.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.

[18]  Melinda G. Hollingshead,et al.  Human Tumor Xenograft Models in NCI Drug Development , 1997 .

[19]  M R Grever,et al.  In vivo cultivation of tumor cells in hollow fibers. , 1995, Life sciences.

[20]  W. Plunkett,et al.  Action of 9-beta-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism. , 1991, Molecular pharmacology.

[21]  D. Carson,et al.  Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. , 1990, The New England journal of medicine.

[22]  K. Paull,et al.  Preclinical antitumor activity of an alpha-picoline derivative, penclomedine (NSC 338720), on human and murine tumors. , 1989, Cancer research.

[23]  H. Osada,et al.  A new biological role of sangivamycin; inhibition of protein kinases. , 1989, The Journal of antibiotics.

[24]  R. Bell,et al.  Sangivamycin, a nucleoside analogue, is a potent inhibitor of protein kinase C. , 1988, The Journal of biological chemistry.

[25]  R. K. Robins,et al.  Purine analogs and related nucleosides and nucleotides as antitumor agents , 1985, Medicinal research reviews.

[26]  M. Cohen,et al.  Comparison of the cellular and RNA-dependent effects of sangivamycin and toyocamycin in human colon carcinoma cells. , 1985, Molecular Pharmacology.

[27]  M. Slavik.  NUCLEOSIDE ANALOGS IN THE TREATMENT OF NEOPLASTIC AND NONNEOPLASTIC DISEASES , 1975, Annals of the New York Academy of Sciences.

[28]  L. Townsend,et al.  SYNTHESIS, CHEMICAL REACTIVITY, AND CHEMOTHERAPEUTIC ACTIVITY OF CERTAIN SELENONUCLEOSIDES AND NUCLEOSIDES RELATED TO THE PYRROLO[2,3‐d]PYRIMIDINE NUCLEOSIDE ANTIBIOTICS * , 1975, Annals of the New York Academy of Sciences.

[29]  K. V. Rao.  Structure of sangivamycin. , 1968, Journal of medicinal chemistry.

[30]  R. K. Robins,et al.  Pyrrolo[2,3-d]pyrimidine nucleoside antibiotics. Total synthesis and structure of toyocamycin, unamycin B, vengicide, antibiotic E-212, and Sangivamycin (BA-90912). , 1968, Journal of the American Chemical Society.

[31]  J. Horton,et al.  Initial toxicity study of sangivamycin (NSC-65346). , 1967, Cancer chemotherapy reports.

[32]  K. Katagiri,et al.  Toyocamycin, a new anti-candida antibiotics. , 1956, Journal of antibiotics (Tokyo. 1968).